Clinical trial
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed…
NCT00058773 · Baylor College of Medicine, Other · Terminated
Key facts
| NCT number | NCT00058773 |
|---|---|
| Title | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease |
| Official title | Administration of Autologous Neomycin Resistant Gene Marked EBV Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving Autologous Bone Marrow Transplant for Relapsed EBV-Positive Lymphoma. |
| Acronym | ANGELA |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hodgkin Disease, Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | Infusion of EBV Specific Cytotoxic T-Lymphocytes |
| Enrollment | 5 |
| Start date | Jan 1, 1996 |
| Primary completion | Apr 1, 2002 |
| Completion | Aug 1, 2006 |
| First posted | Apr 15, 2003 |
| Last update posted | Nov 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: